IceCure Medical Ltd - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
ICCM Nasdaq 3840 www.icecure-medical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IceCure Medical Ltd

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates - May 8th, 2025 9:55 pm
IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation - May 6th, 2025 12:30 pm
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer - Apr 30th, 2025 12:30 pm
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium - Apr 28th, 2025 12:30 pm
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - Apr 22nd, 2025 12:30 pm
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Mar 28th, 2025 1:16 pm
IceCure Medical Full Year 2024 Earnings: Misses Expectations - Mar 28th, 2025 11:09 am
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - Mar 27th, 2025 12:30 pm
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - Mar 24th, 2025 12:30 pm
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - Mar 21st, 2025 12:30 pm
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - Mar 20th, 2025 12:30 pm
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - Mar 18th, 2025 12:30 pm
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology - Mar 17th, 2025 12:30 pm
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery - Mar 10th, 2025 12:30 pm
IceCure seeks Israeli regulatory approval for XSense cryoablation system - Feb 25th, 2025 12:15 pm
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel - Feb 24th, 2025 1:30 pm
IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook - Feb 18th, 2025 10:30 am
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision - Feb 4th, 2025 1:30 pm
IceCure submits application to China’s NMPA for cryoablation system approval - Jan 28th, 2025 12:43 pm
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - Jan 27th, 2025 1:30 pm